Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
Trial purpose
This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).
|
national trial reference number | NCT04938830 |
|
Conditions |
RSV Infection
|
|
Age Range | 0 - 1 |
|
Sex | All |
|
Current trial phase | 3 |
|
Trial start and end dates |
11-30-2021 10-27-2025 |
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.